Ocugen Announces Private Convertible Notes Offering to Deleverage

An announcement from Ocugen ( (OCGN) ) is now available.

On May 4, 2026, Ocugen announced a private offering of convertible notes, including an option for the initial purchaser to buy up to an additional $15 million of notes within 13 days of issuance, as part of broader efforts to strengthen its balance sheet. The company indicated it would allocate about $32.7 million of net proceeds to fully repay outstanding borrowings, accrued interest, and related obligations under its Avenue Loan Agreement, thereby terminating that facility, with remaining funds directed to general corporate purposes.

The repayment plan follows a period of pipeline progress across Ocugen’s gene therapy and biologics portfolio, including completion of Phase 3 enrollment and positive long-term data for its lead retinal gene therapy OCU400 and advancement of OCU410ST and OCU410 toward pivotal stages and regulatory filings. By retiring higher-cost debt while pushing multiple late-stage programs and an inhaled COVID-19 vaccine candidate toward key milestones, Ocugen aims to improve financial flexibility and reinforce its positioning in the competitive retinal gene therapy and ophthalmology space, although its latest cash balance remains a preliminary estimate pending completion of first-quarter 2026 financial statements.

The most recent analyst rating on (OCGN) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Ocugen stock, see the OCGN Stock Forecast page.

Spark’s Take on OCGN Stock

According to Spark, TipRanks’ AI Analyst, OCGN is a Neutral.

Overall score is held back primarily by weak financial performance (minimal revenue, sustained losses/cash burn, and negative equity), partially offset by a positive earnings-call outlook driven by pipeline progress and clearer regulatory timelines. Technicals are mixed but generally supportive over longer moving averages, while valuation support is limited due to ongoing losses and no dividend.

To see Spark’s full report on OCGN stock, click here.

More about Ocugen

Ocugen is a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologics, and vaccines targeting retinal diseases and infectious threats. Its pipeline includes modifier gene therapies such as OCU400 for retinitis pigmentosa, OCU410ST for ABCA4-related retinopathies including Stargardt disease, and OCU410 for geographic atrophy, as well as OCU200 for retinal vascular complications and an inhaled COVID-19 vaccine candidate OCU500.

The company’s late-stage ophthalmology programs are advancing through global regulatory pathways, with OCU400 progressing toward a rolling BLA submission in the third quarter of 2026 and potential approval in 2027, while OCU410ST and OCU410 move through pivotal and Phase 2 trials supported by U.S. and European designations such as ATMP and rare pediatric disease status. As of March 31, 2026, Ocugen had an estimated $32.2 million in cash and 338.3 million common shares outstanding, though the cash figure remains preliminary and unaudited.

Average Trading Volume: 7,892,137

Technical Sentiment Signal: Buy

Current Market Cap: $609.3M

See more data about OCGN stock on TipRanks’ Stock Analysis page.